Wall Street Zen Downgrades Biodexa Pharmaceuticals (NASDAQ:BDRX) to Sell

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of NASDAQ:BDRX opened at $1.08 on Friday. Biodexa Pharmaceuticals has a 1 year low of $1.04 and a 1 year high of $47.79. The business has a fifty day moving average price of $2.79 and a two-hundred day moving average price of $5.03.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.